Amplitude Surgical Announces Its 2022-23 Financial Calendar

VALENCE, France, November 24, 2022–(BUSINESS WIRE)–Regulatory News:

Amplitude Surgical (ISIN : FR0012789667, Mnémo : AMPLI, PEA-PME eligible) (Paris:AMPLI), (“Amplitude” or the “Group“), French leader on the global surgical technology market for lower-limb orthopedics, announces its 2022-23 financial calendar.



2022-23 Q1 Sales

Thursday, November 24, 2022

2022-23 H1 Sales

Thursday, February 23, 2023

2022-23 H1 Results

Wednesday, March 22, 2023

2022-23 Q3 Sales

Thursday, April 20, 2023

2022-23 Full-Year Sales

Thursday, July 20, 2023

2022-23 Full-Year Results

Wednesday, October 18, 2023

2023-24 Q1 Sales

Thursday, November 23, 2023

* Subject to modification. Press releases are published after market closes.

Next press release:
H1 2022-23 sales, on Thursday February 23, 2023, after market.

About Amplitude Surgical

Founded in 1997 in Valence, France, Amplitude Surgical is a leading French player on the global surgical technology market for lower-limb orthopedics. Amplitude Surgical develops and markets high-end products for orthopedic surgery covering the main disorders affecting the hip, knee and extremities, and notably foot and ankle surgery. Amplitude Surgical develops, in close collaboration with surgeons, numerous high value-added innovations in order to best meet the needs of patients, surgeons and healthcare facilities. A leading player in France, Amplitude Surgical is developing abroad through its subsidiaries and a network of exclusive distributors and agents distributing its products in more than 30 countries. Amplitude Surgical operates on the lower-limb market through the intermediary of its Novastep subsidiaries in France and the United States. At June 30, 2022, Amplitude Surgical had a workforce of 460 employees and recorded sales of nearly 104.8 million euros (including foot and ankle activity and before application of IFRS 5).

View source version on


Amplitude Surgical
Dimitri Borchtch
[email protected]
+33 (0)4 75 41 87 41

Investor Relations
Thomas Grojean
[email protected]
+33 (0)1 44 71 94 94

Media Relations
Nicolas Merigeau
[email protected]
+33 (0)1 44 71 94 98

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button